lna043
Recombinant proteinexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 16, 2015 (NCT02491281)
Timeline
Indications
Mechanism of action
- Angiopoietin-related protein 3Supplementation
ANGPTL3 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- lna043
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04814368 | Phase 2 | Aug 27, 2021 | Novartis |
| NCT04864392 | Phase 2 | May 31, 2021 | Novartis |
| NCT04564053 | Phase 1 | Sep 23, 2020 | Novartis |
| NCT03334812 | Phase 2 | Oct 19, 2017 | Novartis |
| NCT03275064 | Phase 2 | Sep 12, 2017 | Novartis |
| NCT02491281 | Phase 1 | Nov 16, 2015 | Novartis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 6 | 6 | 2 | 2015 |
1 organizations
Page 1 / 1